Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer : results from the ABLE feasibility trial
© 2021. The Author(s)..
PURPOSE: Sarcopenia has been identified as an important prognostic factor for patients with cancer. This study aimed at exploring the potential associations between a 6-month physical activity intervention and muscle characteristics, sarcopenia, oxidative stress and toxicities in patients with metastatic breast cancer.
METHODS: Women newly diagnosed with metastatic breast cancer (N = 49) participated in an unsupervised, personalized, 6-month physical activity intervention with activity tracker. Computerized tomography images at the third lumbar vertebra were analysed at baseline, three months and six months to assess sarcopenia (muscle mass index < 40 cm2/m2) and muscle quality (poor if muscle attenuation < 37.8 Hounsfield Units). Oxidative markers included plasma antioxidant enzymes (catalase, glutathione peroxidase and superoxide dismutase activities), prooxidant enzymes (NADPH oxidase and myeloperoxidase activities) and oxidative stress damage markers (advanced oxidation protein products, malondialdehyde (MDA) and DNA oxidation.
RESULTS: At baseline 53% (mean age 55 years (SD 10.41)) were sarcopenic and 75% had poor muscle quality. Muscle cross sectional area, skeletal muscle radiodensity, lean body mass remained constant over the six months (p = 0.75, p = 0.07 and p = 0.75 respectively), but differed significantly between sarcopenic and non-sarcopenic patients at baseline and 6-months. Sarcopenic patients at baseline were more likely to have an increase of MDA (p = 0.02) at 6 months. Being sarcopenic during at least one moment during the 6-month study was associated with a higher risk of developing severe toxicities (grade > 2) (p = 0.02).
CONCLUSIONS: This study suggests potential benefits of physical activity for maintenance of muscle mass. Sarcopenia can alter many parameters and disturb the pro and antioxidant balance.
Errataetall: |
CommentIn: Breast Cancer Res Treat. 2022 Apr;192(2):463. - PMID 34994878 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:188 |
---|---|
Enthalten in: |
Breast cancer research and treatment - 188(2021), 3 vom: 20. Aug., Seite 601-613 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Delrieu, Lidia [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarkers |
---|
Anmerkungen: |
Date Completed 13.07.2021 Date Revised 13.06.2022 published: Print-Electronic CommentIn: Breast Cancer Res Treat. 2022 Apr;192(2):463. - PMID 34994878 Citation Status MEDLINE |
---|
doi: |
10.1007/s10549-021-06238-z |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM325629838 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM325629838 | ||
003 | DE-627 | ||
005 | 20231225192838.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s10549-021-06238-z |2 doi | |
028 | 5 | 2 | |a pubmed24n1085.xml |
035 | |a (DE-627)NLM325629838 | ||
035 | |a (NLM)34013451 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Delrieu, Lidia |e verfasserin |4 aut | |
245 | 1 | 0 | |a Sarcopenia and serum biomarkers of oxidative stress after a 6-month physical activity intervention in women with metastatic breast cancer |b results from the ABLE feasibility trial |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 13.07.2021 | ||
500 | |a Date Revised 13.06.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a CommentIn: Breast Cancer Res Treat. 2022 Apr;192(2):463. - PMID 34994878 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2021. The Author(s). | ||
520 | |a PURPOSE: Sarcopenia has been identified as an important prognostic factor for patients with cancer. This study aimed at exploring the potential associations between a 6-month physical activity intervention and muscle characteristics, sarcopenia, oxidative stress and toxicities in patients with metastatic breast cancer | ||
520 | |a METHODS: Women newly diagnosed with metastatic breast cancer (N = 49) participated in an unsupervised, personalized, 6-month physical activity intervention with activity tracker. Computerized tomography images at the third lumbar vertebra were analysed at baseline, three months and six months to assess sarcopenia (muscle mass index < 40 cm2/m2) and muscle quality (poor if muscle attenuation < 37.8 Hounsfield Units). Oxidative markers included plasma antioxidant enzymes (catalase, glutathione peroxidase and superoxide dismutase activities), prooxidant enzymes (NADPH oxidase and myeloperoxidase activities) and oxidative stress damage markers (advanced oxidation protein products, malondialdehyde (MDA) and DNA oxidation | ||
520 | |a RESULTS: At baseline 53% (mean age 55 years (SD 10.41)) were sarcopenic and 75% had poor muscle quality. Muscle cross sectional area, skeletal muscle radiodensity, lean body mass remained constant over the six months (p = 0.75, p = 0.07 and p = 0.75 respectively), but differed significantly between sarcopenic and non-sarcopenic patients at baseline and 6-months. Sarcopenic patients at baseline were more likely to have an increase of MDA (p = 0.02) at 6 months. Being sarcopenic during at least one moment during the 6-month study was associated with a higher risk of developing severe toxicities (grade > 2) (p = 0.02) | ||
520 | |a CONCLUSIONS: This study suggests potential benefits of physical activity for maintenance of muscle mass. Sarcopenia can alter many parameters and disturb the pro and antioxidant balance | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Metastatic breast cancer | |
650 | 4 | |a Oxidative stress | |
650 | 4 | |a Physical activity | |
650 | 4 | |a Sarcopenia | |
650 | 4 | |a Skeletal muscle index | |
650 | 4 | |a Toxicity | |
650 | 7 | |a Biomarkers |2 NLM | |
700 | 1 | |a Martin, Agnès |e verfasserin |4 aut | |
700 | 1 | |a Touillaud, Marina |e verfasserin |4 aut | |
700 | 1 | |a Pérol, Olivia |e verfasserin |4 aut | |
700 | 1 | |a Morelle, Magali |e verfasserin |4 aut | |
700 | 1 | |a Febvey-Combes, Olivia |e verfasserin |4 aut | |
700 | 1 | |a Freyssenet, Damien |e verfasserin |4 aut | |
700 | 1 | |a Friedenreich, Christine |e verfasserin |4 aut | |
700 | 1 | |a Dufresne, Armelle |e verfasserin |4 aut | |
700 | 1 | |a Bachelot, Thomas |e verfasserin |4 aut | |
700 | 1 | |a Heudel, Pierre-Etienne |e verfasserin |4 aut | |
700 | 1 | |a Trédan, Olivier |e verfasserin |4 aut | |
700 | 1 | |a Crochet, Hugo |e verfasserin |4 aut | |
700 | 1 | |a Bouhamama, Amine |e verfasserin |4 aut | |
700 | 1 | |a Pilleul, Frank |e verfasserin |4 aut | |
700 | 1 | |a Pialoux, Vincent |e verfasserin |4 aut | |
700 | 1 | |a Fervers, Béatrice |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Breast cancer research and treatment |d 1992 |g 188(2021), 3 vom: 20. Aug., Seite 601-613 |w (DE-627)NLM01302132X |x 1573-7217 |7 nnns |
773 | 1 | 8 | |g volume:188 |g year:2021 |g number:3 |g day:20 |g month:08 |g pages:601-613 |
856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10549-021-06238-z |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 188 |j 2021 |e 3 |b 20 |c 08 |h 601-613 |